Breakthrough Therapy Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
TSVT | D | 2seventy bio, Inc. | 0.00 | |
ACHL | F | Achilles Therapeutics plc | 0.00 | |
ASND | D | Ascendis Pharma A/S | 0.00 | |
CMPS | F | COMPASS Pathways Plc | 0.00 | |
CRBU | F | Caribou Biosciences, Inc. | 0.00 | |
GLTO | F | Galecto, Inc. | 0.00 | |
GMAB | F | Genmab A/S | 0.00 | |
GYRE | D | Gyre Therapeutics, Inc. | 0.00 | |
HUMA | B | Humacyte, Inc. | 0.00 | |
PROK | D | ProKidney Corp. | 0.00 |
Related Industries: Biotechnology Long-Term Care Facilities Medical Care Facilities
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
IBB | C | iShares Nasdaq Biotechnology Index Fund | 19.07 | |
BBH | B | Market Vectors Biotech ETF | 17.57 | |
IBBQ | B | Invesco Nasdaq Biotechnology ETF | 17.47 | |
MEDI | D | Harbor Health Care ETF | 16.82 | |
BIS | D | ProShares UltraShort Nasdaq Biotechnology | 12.11 |
Compare ETFs
- Breakthrough Therapy
Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. The FDA's "breakthrough therapy" designation is not intended to imply that a drug is actually a "breakthrough" or that there is high-quality evidence of treatment efficacy for a particular condition; rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases. The FDA has other mechanisms for expediting the review and approval process for promising drugs, including fast track designation, accelerated approval, and priority review.
Popular Now
Recent Comments
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
From the Blog
Featured Articles